PEOR PRONOSTICO CARCINOMA EPIDERMOIDE
NSCLC, non-small cell lung cancer; OS, overall survival
1. Wilson DO et al.
Am J Respir Crit Care Med
2012;185:85–9; 2. Veronesi G et al.
Ann Intern Med
2012;157:776–84;
3. Sandler A et al.
N Engl J Med
2006;355:2542–50; 4. Socinski MA et al.
J Clin Oncol
2012;30:2055–62;
5. Paz-Ares LG et al.
J Clin Oncol
2013;31:2895–902; 6. Scagliotti GV et al.
J Clin Oncol
2008;26:3543–51
•
Based on recent clinical trials, median OS in patients with advanced
squamous NSCLC following 1st-line therapy is 9–11 months
4,6
compared with
12–14 months for those with advanced nonsquamous* disease
3-6
0
2
4
6
8
10
12
14
~30%
Median OS, months
Squamous
Nonsquamous*
Data based on Phase III clinical trials of different 1st-line interventions in advanced NSCLC
3-6
The shaded portion of each bar represents the range
*There are 4 main pathological types of lung cancer (adeno-, squamous cell, small cell and large cell carcinoma). For reasons of clinical consequences,
different pathological types of lung cancer are sometimes grouped into a category (non-small cell carcinoma or nonsquamous non-small cell carcinoma)
when it is necessary or useful to consider them in the same way, even if the tumors are pathologically different
